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Background: Amiodarone is associated with a number of signiﬁcant adverse effects, including elevated
transaminase levels, pulmonary ﬁbrosis, arrhythmia, and thyroid dysfunction. Although thyroid dys-
function is considered to be a common and potentially serious adverse effect of amiodarone therapy, the
exact pathogenesis remains unknown because of its complex manifestations. Therefore, the prevalence
of, and risk factors for, amiodarone-induced thyroid dysfunction in Japanese patients were investigated
in the present study.
Methods: A retrospective analysis of patients treated with amiodarone between January 2012 and
December 2013 was performed. A total of 317 patients with euthyroidism, or subclinical hyperthyroidism
or hypothyroidism, were enrolled in this study.
Results: After being treated with amiodarone, 30 (9.5%) and 60 patients (18.9%) developed amiodarone-
induced hyperthyroidism and amiodarone-induced hypothyroidism, respectively. Ten (33.3%) patients
with amiodarone-induced hyperthyroidism and 40 (66.6%) with amiodarone-induced hypothyroidism
were diagnosed within two years of the initiation of amiodarone therapy. Dilated cardiomyopathy (DCM)
[Adjusted odds ratio (OR) 3.30 (95% conﬁdence interval (CI): 1.26–8.90)], and cardiac sarcoidosis
[Adjusted OR 6.47 (95% CI: 1.60–25.77)] were identiﬁed as predictors of amiodarone-induced hyper-
thyroidism. The baseline free thyroxine (T4) level [Adjusted OR 0.13 (95% CI: 0.03–0.68)], and thyroid-
stimulating hormone (TSH) level [Adjusted OR1.47 (95% CI: 1.26–1.74)] were identiﬁed as predictors of
amiodarone-induced hypothyroidism.
Conclusion: DCM and cardiac sarcoidosis were identiﬁed as risk factors for amiodarone-induced hyper-
thyroidism. Risk factors for amiodarone-induced hypothyroidism included higher baseline TSH level and
lower baseline free T4 level, suggesting that subclinical hypothyroidism may be a potential risk factor for
the development of amiodarone-induced hypothyroidism.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Amiodarone is a potent antiarrhythmic drug that is widely used
in the treatment and prophylaxis of various cardiac arrhythmias,
including supraventricular and ventricular arrhythmias. However,
amiodarone is associated with a number of signiﬁcant adverse
effects [1,2], including elevated transaminase levels, pulmonary
ﬁbrosis, arrhythmia, and thyroid dysfunction. Although thyroid
dysfunction is considered to be a common and potentially seriousblished by Elsevier B.V. This is an
Pharmacy, National Cerebral
Osaka 565-8565, Japan.
:þ81 6 6872 8074.adverse effect of amiodarone therapy [1,3], the exact pathogenesis
remains unknown because of its complex manifestations [4]. The
effects of amiodarone on the thyroid have been attributed to its
iodine content and intrinsic properties [5]. Amiodarone is a ben-
zofuran derivative containing 37.5% iodine by weight. Chronic
treatment with amiodarone has been associated with a forty-fold
increase in plasma and urinary iodide levels [6], which are
responsible for thyroid dysfunction.
The exact incidences of amiodarone-induced hyperthyroidism and
amiodarone-induced hypothyroidism currently remain unknown;
however, the reported frequencies of amiodarone-induced hyper-
thyroidism and amiodarone-induced hypothyroidism vary widely
from 0.8% to 37.8% [7–16] and from 1% to 32% [13,17–20], respectively.
Although amiodarone-induced hypothyroidism is easily controlled byopen access article under the CC BY-NC-ND license
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continuation of amiodarone, the treatment of amiodarone-induced
hyperthyroidism is more complex [21]. Amiodarone-induced hyper-
thyroidism is difﬁcult to treat because of the large accumulation of
iodine in the thyroid gland, and withdrawal of the drug is not effec-
tive because of its extremely prolonged half-life of 50–100 days [6,22].
Furthermore, the discontinuation of life-sustaining antiarrhythmic
medication is not recommended for patients with life-threatening
arrhythmias.
A younger age, male gender, thyroid autoantibody production,
goiter, and low body mass index are associated with amiodarone-
induced hyperthyroidism [12,13,16,23–25], while an older age,
higher baseline thyroid-stimulating hormone (TSH) level, lower left
ventricular ejection fraction, diabetes mellitus, and thyroid auto-
antibody production in women are possible risk factors for
amiodarone-induced hypothyroidism [9,12,13,26–28]. Amiodarone-
induced hyperthyroidism appears to occur more frequently in
geographical areas with low dietary iodine intake, whereas
amiodarone-induced hypothyroidism is more common in iodine-
sufﬁcient areas [26,29,30]. A daily iodine intake of 1–3 mg in Japan
results in a six- to ﬁfteen-fold excess over the recommended daily
intake [31]. Therefore, a higher incidence of amiodarone-induced
hypothyroidism may be more common than amiodarone-induced
hyperthyroidism.
Meanwhile, subclinical thyroid dysfunction, deﬁned as altered
TSH and normal thyroxine (T4) levels, has been reported in more
than 10% of patients with heart failure or dilated cardiomyopathy
(DCM) [32–34]. This suggests that subclinical thyroid dysfunction
is not so rare in patients with cardiovascular diseases treated with
amiodarone, whereas previous reports regarding the prevalence of
risk factors for amiodarone-induced thyroid dysfunction have
focused only on patients with euthyroidism before amiodarone
therapy [11,35]. Consequently, the impact of subclinical thyroid
dysfunction on the development of amiodarone-induced hyper-
thyroidism and amiodarone-induced hypothyroidism is unclear.
The aim of the present study was to determine the prevalence
of, and identify risk factors for, the development of amiodarone-
induced hyperthyroidism and amiodarone-induced hypothyroid-
ism in clinical practice, including not only patients with euthyr-
oidism but also those with subclinical thyroid dysfunction. In
addition, the impact of subclinical thyroid dysfunction on the
development of amiodarone-induced hyperthyroidism and
amiodarone-induced hypothyroidism was investigated.2. Materials and methods
2.1. Study design and data collection
This retrospective cohort study was performed at the National
Cerebral and Cardiovascular Center (NCVC) in Japan, which is a
highly specialized medical center that treats cardiovascular dis-
eases and related disorders, including cardiac diseases, hyperten-
sion, renal diseases, cerebrovascular diseases, and vascular dis-
orders. The treatment of arrhythmias is an important task at the
NCVC. Patients treated for arrhythmias with oral amiodarone
between January 2012 and December 2013 were identiﬁed using
the medical records and computer database of the hospital. The
administration of amiodarone may cause transient thyroid dys-
function within three months of the initiation of therapy [36].
Therefore, only patients having thyroid function data at the
baseline and more than three months after the initiation of
amiodarone therapy were included in the study. Data from thyroid
function tests performed within three months prior to the initia-
tion of amiodarone therapy were used as baseline values. Patients
without baseline data were excluded from the study. Patientsdiagnosed with thyroid dysfunction or treated with antithyroid
drugs or thyroid hormone preparations at the initiation of amio-
darone therapy, were excluded from the study. Demographic,
clinical, and biochemical data, underlying cardiac diseases, the
doses and durations of amiodarone and other medications, and the
results of thyroid function tests were retrieved from the compu-
terized hospital information system as well as medical records.
The duration of amiodarone therapy was deﬁned as the period
between the initiation of amiodarone administration and the lat-
est thyroid function tests. The duration of amiodarone therapy in
patients who developed thyroid dysfunction during the study
period was deﬁned as the period between the initiation of amio-
darone administration and when abnormal thyroid function was
observed.
This study was approved by the Ethics Committees of the NCVC
and Kinki University School of Pharmacy.
2.2. Deﬁnition of thyroid dysfunction
The incidence and pattern of thyroid dysfunction were exclu-
sively based on laboratory diagnostic criteria. Serum TSH, free
triiodothyronine (T3), and free T4 levels were measured using
electrochemiluminescence immunoassay (Elecsys TSH, Elecsys FT3
III, Elecsys FT4 II; Roche Diagnostics, Japan). The normal reference
ranges of thyroid function tests in our laboratory had previously
been standardized as follows: free T4, 1.1–1.8 ng/dL; TSH, 0.5–
5.5 μI U/mL. Patients were diagnosed with hyperthyroidism when a
suppressed TSH level (o0.5 μI U/mL) was found in combination
with an elevated free T4 level (41.8 ng/dL). Patients with sup-
pressed TSH (o0.5 μI U/mL) and normal free T4 (1.1–1.8 ng/dL)
levels were considered to have subclinical hyperthyroidism. Hypo-
thyroidism was diagnosed if the TSH level was elevated
(45.5 μI U/mL) and free T4 level reduced (o1.1 ng/dL), whereas
patients with elevated TSH (45.5 μI U/mL) and normal free T4 (1.1–
1.8 ng/dL) levels were considered to have subclinical hypothyroid-
ism. Patients with normal TSH levels were considered euthyroidism.
Patients with a suppressed TSH level (o0.5 μI U/mL) in combina-
tionwith a suppressed free T4 level (o1.1 ng/dL), and those with an
elevated TSH level (45.5 μI U/mL) in combination with an elevated
free T4 level (41.8 ng/dL), were designated “undetermined”.
Thyroid function tests performed more than three months after
the initiation of amiodarone therapy were used to identify
amiodarone-induced hyperthyroidism and amiodarone-induced
hypothyroidism.
2.3. Statistical analysis
Descriptive statistics were expressed as the mean7standard
deviation (SD) for continuous variables, and as the number of cases
and percentage (%) for categorical variables. Continuous variables
were compared using ANOVA followed by Dunnett's post-test.
Categorical variables were compared using the chi-squared test or
Fisher's exact test. Univariate logistic regression analysis was used
to assess the effect of each variable on amiodarone-induced
hyperthyroidism and amiodarone-induced hypothyroidism. Multi-
variate logistic regression analysis was performed in order to assess
the relationship between baseline clinical variables and the devel-
opment of amiodarone-induced hyperthyroidism and amiodarone-
induced hypothyroidism. All variables were entered into the logistic
models and removed employing the stepwise backward elimination
method if the P value exceeded 0.1. Adjusted odds ratios (ORs), their
95% conﬁdence intervals (CIs), and P values were calculated. JMPs
10.0.2 (SAS Institute Inc., Cary, NC, USA) was used for all statistical
analyses.
Fig. 1. Flowchart of patient selection. A total of 621 patients for whom amiodarone
was prescribed were identiﬁed. Forty patients who were treated with antithyroid
drugs or thyroid hormone preparations and eight patients diagnosed with thyroid
dysfunction at the time of the initiation of amiodarone therapy were excluded from
the study. Eighty-six patients without tests for thyroid function within three
months prior to the initiation of amiodarone therapy and 170 patients without tests
for thyroid function more than three months after the initiation of amiodarone
therapy were excluded from the study. A total of 317 patients were enrolled in
the study.
Table 1
Baseline characteristics of 317 patients in the present study.
Number of patients 317
Age (years)a 58.5716.6
Male (%) 233 (73.5)
Cardiac diagnoses
Dilated cardiomyopathy (%) 88 (27.8)
Hypertrophic cardiomyopathy (%) 53 (16.7)
Ischemic cardiomyopathy (%) 17 (5.4)
Cardiac sarcoidosis (%) 24 (7.6)
Other disease (%) 135 (42.6)
Hypertension (%) 120 (37.9)
Diabetes mellitus (%) 64 (20.2)
Dyslipidemia (%) 124 (39.1)
Baseline free T4 (ng/dL)a 1.4270.25
Baseline TSH (μI U/mL)a 3.2772.54
Thyroid status at the initiation of amiodarone
Euthyroidism (male/female) 256 (186/70)
Subclinical hypothyroidism (male/female) 52 (40/12)
Subclinical hyperthyroidism (male/female) 9 (7/2)
Amiodarone use
Duration (days)a 9567881
Cumulative dose (g)a 98.17109.9
Average dose (mg/day)a 112.7764.5
T4: thyroxine.
TSH: thyroid-stimulating hormone.
a Mean7SD.
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Fig. 1 shows the ﬂowchart for study inclusion. Between January
2012 and December 2013, a total of 621 patients for whom
amiodarone was prescribed for arrhythmia, were identiﬁed from
the computer database of the hospital. Forty patients who were
treated with antithyroid drugs or thyroid hormone preparations
and eight patients diagnosed with thyroid dysfunction at the time
of initiation of amiodarone therapy were excluded from the study.
Eighty-six patients without tests for thyroid function within three
months prior to the initiation of amiodarone therapy and 170
patients without tests for thyroid function more than three
months after the initiation of amiodarone therapy were excluded
from the study. A total of 317 patients fulﬁlled the inclusion cri-
teria and were enrolled in the study.
The baseline characteristics of the study patients are summar-
ized in Table 1. DCM was the most common underlying cardiac
abnormality (27.8%) for patients receiving amiodarone therapy.
The mean age for the start of amiodarone therapy was 58.5716.6
years, and 73.5% of the patients were males. There were 256
patients with euthyroidism, 9 patients with subclinical hyper-
thyroidism, and 52 patients with subclinical hypothyroidism.
The characteristics of patients with normal and abnormal
thyroid function after amiodarone therapy are presented in
Table 2. After being treated with amiodarone, 30 (9.5%) and 60
(18.9%) patients developed amiodarone-induced hyperthyroidism
and amiodarone-induced hypothyroidism, respectively. At the end
of the follow-up period, there were 9 patients (2.8%) with sub-
clinical hyperthyroidism, 81 (25.6%) with subclinical hypothyr-
oidism, and 22 (6.9%) were “undetermined”. The remaining
patients (36.3%) maintained a euthyroidism state throughout the
study period.
No differences were found regarding sex, average dose of
amiodarone per day, and the prevalence of DCM, hypertrophic
cardiomyopathy, ischemic cardiomyopathy, diabetes mellitus, and
dyslipidemia among the groups. Compared with euthyroidism
patients, those with amiodarone-induced hyperthyroidism were
younger at the initiation of amiodarone therapy and at the end of
the follow-up period, and had a lower prevalence of hypertension.
The duration of amiodarone therapy was shorter in patients with
amiodarone-induced hypothyroidism than in patients with
euthyroidism. Patients with subclinical hyperthyroidism had a
higher prevalence of cardiac sarcoidosis than euthyroidism
patients. Patients with subclinical hypothyroidism had a shorter
duration of amiodarone therapy and smaller cumulative doses of
amiodarone than euthyroidism patients. Free T4 levels were
similar between patients with subclinical thyroid dysfunction and
euthyroidism patients.
As shown in Fig. 2, 40 out of the 60 patients (66.6%) who
developed amiodarone-induced hypothyroidism, and 10 out of the
30 patients (33.3%) who developed amiodarone-induced hyper-
thyroidism, were diagnosed within two years of initiation of
amiodarone therapy. Amiodarone-induced hypothyroidism
developed signiﬁcantly earlier than amiodarone-induced hyper-
thyroidism following initiation of amiodarone therapy (Po0.003).
The relationship between thyroid function status before and
after amiodarone therapy is presented in Table 3, which shows the
distribution of patients with thyroid dysfunction before and after
amiodarone therapy. Among 256 patients with euthyroidism at
baseline, 27 (10.5%) and 41 patients (16.0%) developed amiodarone-
induced hyperthyroidism and amiodarone-induced hypothyroid-
ism, respectively. However, 17 out of the 52 patients (32.7%) with
subclinical hypothyroidism at baseline developed amiodarone-
induced hypothyroidism after the therapy. Two out of the 52
patients (3.8%) with subclinical hypothyroidism at baseline devel-
oped amiodarone-induced hyperthyroidism.A stepwise multivariate logistic regression analysis identiﬁed
patient age at baseline [Adjusted OR 0.95 (95% CI: 0.92–0.97)],
DCM [Adjusted OR 3.30 (95% CI: 1.26–8.90)], and cardiac sarcoi-
dosis [Adjusted OR 6.47 (95% CI: 1.60–25.77)] as predictors of
amiodarone-induced hyperthyroidism (Table 4). In the analysis of
amiodarone-induced hypothyroidism, baseline free T4 level
[Adjusted OR 0.13 (95% CI: 0.03–0.63)], TSH level [Adjusted OR1.47
(95% CI: 1.26–1.74)], and average dose of amiodarone per day
[Adjusted OR 1.01 (95% CI: 1.00–1.01)] were identiﬁed as pre-
dictors (Table 5).
Table 2
Characteristics of patients with normal and abnormal thyroid function after amiodarone therapy.
Patients Euthyroidism Amiodarone-induced
hyperthyroidism
Amiodarone-induced
hypothyroidism
Subclinical
hyperthyroidism
Subclinical
hypothyroidism
Undetermined
Number of patients 115 30 60 9 81 22
Baseline characteristics
Age at the initiation of amiodarone
therapy (years)a
60.4715.9 46.5714.7n 62.8715.6 55.1712.5 59.3716.2 51.6719.3
Male (%) 81 (70.4) 24 (80.0) 43 (71.7) 7 (77.8) 63 (77.8) 15 (68.2)
Cardiac Diagnoses
Dilated cardiomyopathy (%) 25 (21.7) 13 (43.3) 16 (26.7) 1 (11.1) 26 (32.1) 7 (31.8)
Hypertrophic cardiomyopathy
(%)
20 (17.4) 3 (10.0) 15 (25.0) 2 (22.2) 11 (13.6) 2 (9.1)
Ischemic cardiomyopathy (%) 9 (7.8) 2 (6.7) 3 (5.0) 0 (0) 3 (3.7) 0 (0)
Cardiac sarcoidosis (%) 8 (7.0) 5 (16.7) 2 (3.3) 3 (33.3)n 3 (3.7) 3 (13.6)
Other disease (%) 53 (46.1) 7 (23.3) 24 (40.0) 3 (33.3) 38 (46.9) 10 (45.5)
Indication for amiodarone
Atrial tachyarrhythmia (%) 37 (32.2) 6 (20.0) 13 (21.7) 3 (33.3) 18 (22.2) 6 (27.3)
Ventricular tachyarrhythmia (%) 78 (67.8) 24 (80.0) 47 (78.3) 6 (66.7) 63 (77.8) 16 (72.7)
Hypertension (%) 49 (42.6) 5 (16.7)* 27 (45.0) 5 (55.6) 30 (37.0) 4 (18.2)
Diabetes mellitus (%) 24 (20.9) 1 (3.3) 12 (20.0) 4 (44.4) 18 (22.2) 5 (22.7)
Dyslipidemia (%) 50 (43.5) 7 (23.3) 26 (43.3) 5 (55.6) 32 (39.5) 4 (18.2)
Baseline free T4 (ng/dL)a 1.4470.23 1.5870.30n 1.3370.22n 1.4970.33 1.3870.23 1.5070.24
Baseline TSH (μI U/mL)a 2.3571.97 2.5072.01 4.3872.82n 1.5670.75 3.7972.33n 4.9473.61n
Age at the end of the follow-up
(years)a
63.5716.1 49.9714.9n 64.8715.7 58.8711.4 61.4716.3 54.0719.0
Amiodarone use
Duration (days)a 11227914 12707934 7347660n 12757836 7667899n 8327857
Cumulative dose (g)a 112.97115.3 132.17112.8 86.0798.1 190.87109.9 65.3797.8n 89.67113.3
Average dose (mg/day)a 105.4761.7 115.2759.6 124.5764.9 144.1745.5 109.3771.8 115.5760.2
T4: thyroxine.
TSH: thyroid-stimulating hormone.
a Mean7SD.
n Signiﬁcant difference between euthyroidism group and other groups (Po0.05).
Fig. 2. Number of patients who developed amiodarone-induced hyperthyroidism
and amiodarone-induced hypothyroidism after the initiation of amiodarone
therapy.
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We found the prevalences of amiodarone-induced hyperthyr-
oidism and amiodarone-induced hypothyroidism to be 9.5% and
18.9%, respectively, among our study patients, with amiodarone-
induced hypothyroidism occurring more frequently than
amiodarone-induced hyperthyroidism.
The prevalence of amiodarone-induced hyperthyroidism was
higher in our study than in previous studies conducted in Asian
countries [13,19,35] that included only patients with euthyroid-
ism. The prevalence of amiodarone-induced hyperthyroidism was
previously reported to be 4.0% in Taiwan [19] and 6% in theChinese population living in Hong Kong [13]. Additionally, a recent
study found that the prevalence of amiodarone-induced hyper-
thyroidism was 5.8% in Japan [35]. In our study, patients with
subclinical hyperthyroidism and hypothyroidism were included in
the analysis in order to determine the predictors of amiodarone-
induced hypothyroidism and amiodarone-induced hyperthyroid-
ism in clinical practice. Patients with subclinical thyroid dysfunc-
tion are also treated with amiodarone. Therefore, predictors
associated with the clinical use of amiodarone therapy need to be
investigated. In our analysis of 256 patients with euthyroidism at
baseline, 10.5% and 16.0% of patients developed amiodarone-
induced hyperthyroidism and amiodarone-induced hypothyroid-
ism, respectively. Therefore, the high prevalence of amiodarone-
induced hyperthyroidism in our study may not be attributable to
the inclusion of patients with subclinical thyroid dysfunction.
Meanwhile, the prevalence of amiodarone-induced hypothyroid-
ism was similar to previously reported prevalences in Asian
countries (13.1% in Taiwanese and 22% in the Hong Kong Chinese
population).
We identiﬁed several candidates as potential predictors of
amiodarone-induced hyperthyroidism and amiodarone-induced
hypothyroidism in the patient characteristic analysis. Baseline free
T4 and baseline TSH levels, and the duration of amiodarone therapy,
were considered as candidate predictors of amiodarone-induced
hypothyroidism. Patients with subclinical hypothyroidism at the
initiation of amiodarone therapy were more likely to develop
amiodarone-induced hypothyroidism. In the present study, 41 out of
the 256 patients (16.0%) with euthyroidism at the initiation of
amiodarone therapy developed amiodarone-induced hypothyroidism.
Meanwhile, 17 out of the 52 patients (32.7%) with subclinical hypo-
thyroidism at the initiation of amiodarone therapy developed
amiodarone-induced hypothyroidism. Subclinical hypothyroidism
may be a potential risk factor for amiodarone-induced hypothyroid-
ism. In order to test this hypothesis, a stepwise multivariate logistic
Table 3
Distribution of patients with thyroid dysfunction before and after amiodarone therapy.
Before amiodarone therapy
After amiodarone therapy
Euthyroidism Amiodarone-induced
hyperthyroidism
Amiodarone-induced
hypothyroidism
Subclinical
hyperthyroidism
Subclinical
hypothyroidism
Undetermined
Euthyroidism (%) 256 101 (39.5) 27 (10.5) 41 (16.0) 8 (3.1) 65 (25.4) 14 (5.5)
Subclinical hyperthyroidism (%) 9 4 (44.4) 1 (11.1) 2 (22.2) 1 (11.1) 0 1 (11.1)
Subclinical hypothyroidism (%) 52 10 (19.2) 2 (3.8) 17 (32.7) 0 16 (30.8) 7 (13.5)
Total (%) 317 115 (36.3) 30 (9.5) 60 (18.9) 9 (2.8) 81 (25.6) 22 (6.9)
Table 4
Logistic regression analysis including risk factors for the development of amiodarone-induced hyperthyroidism.
Variables Univariate OR (95% CI) P value Adjusted OR (95% CI) P value
Age at the initiation of amiodarone therapy (years) 0.95 (0.93–0.98) o0.001 0.95 (0.92–0.97) o0.001
Male 1.69 (0.66–4.86) 0.285
Dilated cardiomyopathy 2.75 (1.17–6.44) 0.021 3.30 (1.26–8.90) 0.016
Hypertrophic cardiomyopathy 0.52 (0.12–1.69) 0.302
Ischemic cardiomyopathy 0.84 (0.12–3.50) 0.828
Cardiac sarcoidosis 2.68 (0.75–8.73) 0.122 6.47 (1.60–25.77) 0.007
Hypertension 0.27 (0.08–0.70) 0.006
Diabetes mellitus 0.13 (0.01–0.66) 0.010
Dyslipidemia 0.40 (0.15–0.96) 0.039
Baseline free T4 (ng/dL) 9.34 (1.84–52.6) 0.008
Baseline TSH (μI U/mL) 1.04 (0.84–1.25) 0.706
Duration of amiodarone therapy (days) 1.00 (1.00–1.00) 0.434
Cumulative dose of amiodarone (g) 1.00 (1.00–1.00) 0.746
Average dose of amiodarone (mg/day) 1.00 (0.99–1.01) 0.868
OR: odds ratio.
CI: conﬁdence interval.
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T4 level, higher baseline TSH level, and higher average dose of
amiodarone per day were identiﬁed as independent risk factors for
the development of amiodarone-induced hypothyroidism. Higher
baseline TSH level supports the hypothesis that subclinical hypo-
thyroidism is a predictor of the development of amiodarone-induced
hypothyroidism. Although average dose of amiodarone per day was
also statistically signiﬁcant as a predictor of amiodarone-induced
hypothyroidism, the relationship between amiodarone dosage and
amiodarone-induced hypothyroidism currently remains unclear.
Additionally, both sample size and effect size of the odds ratios were
small in the present study. Therefore, we cannot conclude that aver-
age dose of amiodarone per day is a clinically signiﬁcant risk factor,
and further studies are needed to elucidate this issue. In the present
study, 40 out of the 60 patients (66.6%) who developed amiodarone-
induced hypothyroidism were diagnosed within two years of initia-
tion of amiodarone therapy. This result is consistent with previous
studies, suggesting that a shorter duration of amiodarone use is
associated with the development of amiodarone-induced hypothyr-
oidism [19,37]. Lower baseline free T4 and higher baseline TSH levels,
including those for subclinical hypothyroidism, appear to be potential
risk factors for amiodarone-induced hypothyroidism in patients
receiving amiodarone therapy. These ﬁndings suggest that careful
medical surveillance for amiodarone-induced hypothyroidism is
needed in patients with subclinical hypothyroidism at baseline.
Age at initiation of amiodarone therapy, hypertension, baseline
free T4 level, and age at the end of follow-up were evaluated as
candidate predictors of amiodarone-induced hyperthyroidism. In
order to test this hypothesis, a stepwise multivariate logistic
regression analysis was performed. Consequently, a younger age at
the initiation of amiodarone, DCM, and cardiac sarcoidosis were
identiﬁed as independent risk factors for the development ofamiodarone-induced hyperthyroidism. Previous studies suggested
that young age is a risk factor for amiodarone-induced hyperthyr-
oidism [12,13,19,35], and our results are consistent with these stu-
dies. Although, we cannot conclude that age at the initiation of
amiodarone therapy was a clinically signiﬁcant risk factor for
amiodarone-induced hyperthyroidism in the present study, given
both the low sample size and the small effect size of the odds ratio.
In this study, DCM and cardiac sarcoidosis were identiﬁed as risk
factors for the development of amiodarone-induced hyperthyroid-
ism. The relationship between cardiac sarcoidosis and thyroid dys-
function has not yet been elucidated. However, Malli et al. reported
that thyroid disorders are common in sarcoidosis patients [38]. This
relationship may be the result of increased levels of thyroid anti-
bodies. Serological and ultrasonographic indices of thyroid auto-
immunity are signiﬁcantly higher in patients with sarcoidosis,
suggesting that the relationship between this disease and thyroid
disorders has an immunological basis. The relationship between
thyroid dysfunction and sarcoidosis needs to be investigated fur-
ther. The relationship between DCM and amiodarone-induced
hyperthyroidism also remains unclear. An experimental study sug-
gested that amiodarone increases reactive oxygen species con-
centrations [39]. When amiodarone-induced pro-oxidant activity
exceeds the endogenous antioxidant capacity, thyroid follicles are
destroyed, potentially resulting in amiodarone-induced hyperthyr-
oidism [40]. On the other hand, previous studies reported that
oxidative stress is elevated in the myocardia of patients with DCM
[41,42], and the levels of markers of oxidative DNA damage are also
higher in the sera of patients with DCM [42]. Therefore, patients
with DCM may be more sensitive to oxidative stress induced by the
administration of amiodarone and are more likely to develop
amiodarone-induced hyperthyroidism. Future studies are required
Table 5
Logistic regression analysis including risk factors for the development of amiodarone-induced hypothyroidism.
Variables Univariate OR (95% CI) P value Adjusted OR (95% CI) P value
Age at the initiation of amiodarone therapy (years) 1.01 (0.99–1.03) 0.347
Male 1.06 (0.54–2.15) 0.865
Dilated cardiomyopathy 1.31 (0.63–2.68) 0.468
Hypertrophic cardiomyopathy 1.58 (0.73–3.37) 0.238
Ischemic cardiomyopathy 0.62 (0.13–2.17) 0.472
Cardiac sarcoidosis 0.46 (0.07–1.91) 0.306
Hypertension 1.10 (0.59–2.07) 0.762
Diabetes mellitus 0.95 (0.42–2.03) 0.892
Dyslipidemia 0.99 (0.53–1.86) 0.985
Baseline free T4 (ng/dL) 0.11 (0.02–0.47) 0.003 0.13 (0.03–0.63) 0.014
Baseline TSH (μI U/mL) 1.42 (1.23–1.66) o0.001 1.47 (1.26–1.74) o0.001
Duration of amiodarone therapy (days) 1.00 (1.00–1.00) 0.003
Cumulative dose of amiodarone (g) 1.00 (0.99–1.00) 0.114
Average dose of amiodarone (mg/day) 1.01 (1.00–1.01) 0.055 1.01 (1.00–1.01) 0.016
OR: odds ratio.
CI: conﬁdence interval.
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opment of amiodarone-induced hyperthyroidism.
Patients with subclinical hypothyroidism at the initiation of
amiodarone therapy were less likely to develop amiodarone-
induced hyperthyroidism. Two out of the 52 patients (3.8%) with
subclinical hypothyroidism at the baseline developed amiodarone-
induced hyperthyroidism. Subclinical hypothyroidism may be
associated with a decreased risk of amiodarone-induced hyper-
thyroidism, whereas subclinical hyperthyroidism at baseline may
not be associated with a risk of amiodarone-induced hyperthyr-
oidism or amiodarone-induced hypothyroidism.
Among 256 patients with euthyroidism at baseline, 65 patients
(25.4%) and 8 patients (3.1%) had developed subclinical hypothyr-
oidism and subclinical hyperthyroidism respectively, after the
initiation of amiodarone therapy. During longer observation of
patients with continuous administration of amiodarone and follow-
up thyroid function tests, 17 out of the 34 patients (50.0%) with
subclinical hypothyroidism became euthyroidism, while the other
half remained subclinical hypothyroidism (the mean duration of
follow-up after ﬁrst diagnosis of subclinical hypothyroidism being
6657752 days). Meanwhile, all 5 patients with subclinical hyper-
thyroidism became euthyroidism in a subsequent follow-up (the
mean duration of follow-up after ﬁrst diagnosis of subclinical
hyperthyroidism being 8927662 days). These results suggest that
subclinical hypothyroidism in the course of amiodarone therapy
may need recognition as the prodromal phase of future
amiodarone-induced hypothyroidism.
Several potential limitations need to be considered when
interpreting the results obtained in the present study. This was an
observational study with a retrospective design and was per-
formed at a single highly specialized national center that treats
cardiovascular diseases and related disorders. Although DCM and
cardiac sarcoidosis identiﬁed in this study may be risk factors in
certain populations, it remains uncertain whether these risk fac-
tors are applicable to all patients. Age at the initiation of amio-
darone therapy and average dose of amiodarone per day were also
statistically signiﬁcant as risk factors in this study, though it
remains uncertain whether they are of signiﬁcant clinical value.
Furthermore, the available sample size in our study was small. The
incidence and pattern of thyroid dysfunction were also exclusively
based on laboratory diagnostic criteria in the NCVC. Different
diagnostic criteria for thyroid dysfunction may affect the pre-
valences of amiodarone-induced hyperthyroidism and
amiodarone-induced hypothyroidism. In addition, thyroid auto-
antibody levels were not measured in most patients in the present
study. Patients with subclinical thyroid dysfunction were includedin the analysis in order to determine predictors associated with
the clinical use of amiodarone therapy. Therefore, it cannot be
denied that thyroid autoimmune disease is associated with thyroid
dysfunction after the initiation of amiodarone therapy in patients
with subclinical thyroid dysfunction. Despite these limitations,
some potential predictors of amiodarone-induced hyperthyroid-
ism and amiodarone-induced hypothyroidism were identiﬁed in
the present study. Amiodarone-induced hyperthyroidism and
amiodarone-induced hypothyroidism are serious concerns in
amiodarone therapy; therefore, further studies are required in
order to conﬁrm these results.5. Conclusion
The risk factors for amiodarone-induced hypothyroidism in our
study included higher baseline TSH level and lower baseline free
T4 level. Subclinical hypothyroidism may be a potential risk factor
for the development of amiodarone-induced hypothyroidism. In
contrast, DCM and cardiac sarcoidosis were identiﬁed as risk fac-
tors for amiodarone-induced hyperthyroidism.Conﬂict of interest
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